Evidence map›Paper›PMID 42053392›Full record

ReviewJournal of virology2026

Human infection with pseudorabies virus: review of evidence, risk assessment, and future directions.

Herman W Favoreel

Abstract readReview
In one paragraph

Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Herman W FavoreelDepartment of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Ghent, Belgium.ORCID 0000-0003-4993-6857

Funding

Fonds Wetenschappelijk Onderzoek G081125NUniversiteit Gent GOA015-23, BOF24Y2021017
6 · The paper itself

Abstract

Pseudorabies virus (PRV) is an alphaherpesvirus with a broad host range, with the pig as its natural host. Although PRV can use human cell surface receptors for cell entry, humans and higher primates have been considered as refractory or showing very limited susceptibility to PRV infection. Between 1914 and 2011, only 17 cases of suspected human PRV infection were described, typically displaying temporal and mild/intermediate disease symptoms, mostly consisting of severe itching. No neurological complications were reported. In addition, in 1970, one researcher conducted a repetitive PRV self-inoculation experiment, which resulted in neither symptoms nor seroconversion. However, since 2011 and mostly based on next-generation sequencing on cerebrospinal fluid, 34 human cases of suspected PRV infection have been reported, all of which were linked with severe, life-threatening encephalitis and/or visual impairment. All these cases were reported in China, where there has been a concomitant surge in outbreaks of PRV strains that show genetic differences compared to classical PRV strains. All suspected recent cases of human PRV infection had (occupational) contact with raw pig meat and often had skin damage on the hands or fingers, or direct eye contact with potentially PRV-infected material. Importantly, human-to-human PRV infection has never been reported. Although the risk for human PRV infection remains very low, these recent developments should guide increased efforts to eradicate PRV from domestic pig populations, increase protection of individuals at risk, and increase research on improved diagnostics, effective antivirals, and a better understanding of the host and viral factors that determine human susceptibility or resistance to PRV infection.

Indexed as

Herpesvirus 1, SuidPseudorabiesAnimalsChinaHumansRisk AssessmentSwine

Identifiers

PMID42053392
PMCPMC13185634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.